Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Up 170.3% in April

Posted by Geri Gentry on May 16th, 2026

Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totaling 199,019 shares, an increase of 170.3% from the April 15th total of 73,622 shares. Based on an average daily volume of 9,855,381 shares, the short-interest ratio is currently 0.0 days. Approximately 2.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is owned by institutional investors.

Capstone Therapeutics Stock Performance

Shares of NASDAQ CAPS traded down $0.01 during trading on Friday, reaching $0.28. The stock had a trading volume of 524,995 shares, compared to its average volume of 680,230. Capstone Therapeutics has a one year low of $0.26 and a one year high of $3.29. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.26 and a current ratio of 1.00. The stock has a market cap of $4.06 million, a PE ratio of -0.08 and a beta of -1.52. The firm’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.68.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Stock Report on CAPS

Capstone Therapeutics Company Profile

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.